Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) announced that it has entered in to definitive agreement for 3,669,724 shares at a price of $2 per share for the gross proceeds of $7,339,448 and 1,834,862 warrants at a price of $0.36 for gross proceeds of $660,550 for aggregate gross proceeds of $7,999,998 on April 28, 2021. Warrants issue in the transaction can be exercised in to 1,834,862 shares at a an exercise price of $2.50 per share and will expire five years from the date of issuance. The transaction is expected to close on or about April 30, 2021, subject to the satisfaction of customary closing conditions. The transaction is being made pursuant to the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission.